Precursor and borderline lesions of the thyroid (indolent lesions of epithelial origin): from theory to practice

Gland Surg. 2020 Oct;9(5):1724-1734. doi: 10.21037/gs-20-429.

Abstract

The precursor lesions of thyroid neoplasms can arise from either C cells or follicular cells. Although MTC has an established and recognized precursor lesion, the C-cell hyperplasia, the same does not occur for the follicular cell-derived tumors, which are much more frequent. One of the significant obstacles to recognizing follicular cell-derived precursor lesions (FCPL) is the lack of refinement of the morphological spectrum and biology of these putative premalignant lesions. What are the "gold standard" histological criteria in thyroid pathology to identify the progression of dysplasia to cancer? Diagnostical irreproducibility and misnomer in the terminology of some FCPLs have been lying behind the answer to this question. The last past decades' advances in molecular pathology allow us to transform the knowledge in thyroid pathology to cancer prevention and early detection, which will only be possible by improving our understanding of the nature of thyroid precursor and borderline lesions. This review, amassed with the augmented expertise of thyroid pathology documented in the literature, is an attempt at underlining the present understanding of precursor and borderline lesions of the thyroid, with a particular highlight on practice differences in Asian and Western geographies.

Keywords: Thyroid gland; borderline lesions; follicular cells; indolent lesion of epithelial origin; indolent lesion of epithelial origin (IDLE); low-risk carcinomas; overtreatment; precursor lesions.

Publication types

  • Review